tradingkey.logo
tradingkey.logo
Suchen

STAAR Surgical Co

STAA
Zur Watchlist hinzufügen
27.790USD
-0.360-1.28%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
1.38BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über STAAR Surgical Co Unternehmen

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

STAAR Surgical Co Informationen

BörsenkürzelSTAA
Name des UnternehmensSTAAR Surgical Co
IPO-datumFeb 24, 1992
CEOFarrell (Stephen C)
Anzahl der mitarbeiter1157
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 24
Addresse1911 Walker Ave
StadtMONROVIA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91016
Telefon16263037902
Websitehttps://www.staar.com/
BörsenkürzelSTAA
IPO-datumFeb 24, 1992
CEOFarrell (Stephen C)

Führungskräfte von STAAR Surgical Co

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
82.21K
+57.24%
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
78.19K
+13.66%
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
69.54K
+18.35%
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
33.42K
+25.17%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
30.18K
+72.87%
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
18.65K
+53.97%
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
11.16K
+95.74%
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.10K
--
Mr. Brian Moore
Mr. Brian Moore
Vice President - Investor Relations and Corporate Development
Vice President - Investor Relations and Corporate Development
--
--
Ms. Lilian Zhou
Ms. Lilian Zhou
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
82.21K
+57.24%
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
78.19K
+13.66%
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
69.54K
+18.35%
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
33.42K
+25.17%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
30.18K
+72.87%
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
18.65K
+53.97%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von STAAR Surgical Co?

Die fünf größten Anteilseigner von STAAR Surgical Co sind: Mr. Stephen C. (Steve) Farrell, CPA

Wie viele Institutionen halten Anteile an STAAR Surgical Co (STAA)?

Mit Stand vom 2026Q1 halten 543 Institutionen Anteile an STAAR Surgical Co, mit einem Gesamtmarktwert von etwa 58.06M, was 116.62% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -10575638.00 gestiegen.